American Association for Cancer Research

Poster Session A

Poster Session A

Tuesday, January 7 • 12:30 p.m.-2:30 p.m.

In board assignment order

  • A01   KRAS molecular profiling in non-squamous non-small cell lung cancer (NSCLC), Nagla Abdel Karim
  • A02   Targeted deep sequencing of second biopsy tissues from patients with acquired resistance(AR) to EGFR tyrosine kinase inhibitors harboring EGFR mutations: Preliminary results, Myung-Ju Ahn
  • A03   Airway gene expression alterations associated with early lung carcinogenesis, Jennifer E. Beane
  • A04, PR01   Recurrent oncogenic mutations in the small GTPase RIT1 activate PI3K and MEK, Alice H. Berger
  • A05   Ubiquilin1 represses migration and epithelial to mesenchymal transition of human non-small cell lung cancer cells, Levi J. Beverly
  • A06   Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients with acquired resistance to erlotinib, Trever G. Bivona
  • A07   MTI-101 induces synergistic cell kill in combination with Erlotinib in EGFR driven lung cancer models, Lisa E. Blumencranz
  • A08   Prognostic value of circulating angiogenesis biomarkers in rapidly progressing NSCLC, Jeffrey A. Borgia
  • A09   Selector (HaloPlex) targeted resequencing of formalin-fixed paraffin-embedded (FFPE) specimens for mutation diagnostics in NSCLC, Johan Botling
  • A10   Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer, John Brognard
  • A11   The function of B cells in non-small cell lung cancer patients, Tullia C. Bruno
  • A12   Screening for TWIST1 inhibitors as a novel therapy for oncogene driven lung cancer, Timothy F. Burns
  • A13   Pharmacologic targeting of IL-6 suppresses tumor progression in a non-small cell lung cancer mouse model with K-ras mutation through re-educating the tumor microenvironment, Mauricio S. Caetano
  • A14   Novel activating EGFR mutation-specific antibodies for lung adenocarcinoma: Highly specific detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry, Jin-Haeng Chung
  • A15, PR02   Comprehensive genomic characterization of lung adenocarcinoma by the cancer genome atlas investigators (TCGA), Eric Collisson
  • A16   Induction of Activating Transcription Factor 3 is associated with cisplatin responsiveness in NSCLC: A potential predictive biomarker of response, Jim Dimitroulakos
  • A17   A blood test for early detection of lung cancer using a mixed panel of tumor proteins and autoantibodies, Victoria Doseeva
  • A18   EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumors to TopoII inhibitors, Christine M. Fillmore
  • A19   Origin and functional role of plasma circulating miRNAs, Orazio Fortunato
  • A20   MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity, Edward B. Garon
  • A21   microRNA-200 regulates tumor cell PD-L1 expression to control lung cancer metastasis, Don L. Gibbons
  • A22   Detection of protein complexes using proximity ligation assays in EML4-ALK rearranged NSCLC, Richard D. Hall
  • A23   Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer, Hisashi Harada
  • A24   Development and clinical validation of a quantitative mass spectrometric assay for PD-L1 protein in FFPE NSCLC samples, Todd Hembrough
  • A25   GLI inhibition as a new strategy to treat lung squamous cell carcinoma, Lingling Huang
  • A26   Imprime PGG improves the efficacy of carboplatin, paclitaxel and cetuximab chemoimmunotherapy of advanced non-small cell lung cancer (NSCLC), Richard D. Huhn
  • A27   Loss of PABPN1 and alternative polyadenylation yield poor prognosis in non-small cell lung cancer, Junji Ichinose
  • A28   Oncogenic ARAF mutation in a metastatic lung adenocarcinoma from a patient exhibiting sustained sorafenib response, Marcin Imielinski
  • A29   Advanced nano-proteomics based on ultrasensitive CE to quantitate protein expression/phosphorylation levels: Discovery of novel proteins involved in chemoresistance/invasion of lung cancer cells, Ronald R. Fiscus
  • A30   Melatonin suppresses invasion and epithelial to mesenchymal transition in non-small cell lung cancer cells via inhibition of ZNF746 signaling, Bonglee Kim
  • A31   Comparison of direct sequencing and peptide nucleic acid clamping of EGFR gene in patients with non-small cell lung cancer, Young-Chul Kim
  • A32   RET fusion gene: translation to personalized lung cancer therapy, Takashi Kohno
  • A33, PR08   Pro-surfactant protein B as a biomarker for lung cancer prediction, Ayumu Taguchi
  • A34   Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic, Glen J. Weiss
  • A35   A Pluripotency Reporter defines lung cancer cells with tumor-initiating properties, Ana I. Robles
  • A36   Aberrant regulation of asymmetric cell division by mutant p53 in lung cancer, Brid M. Ryan
  • A37   Ectopic Claudin 6 and 18.2 expression as potential treatment target in non-small cell lung cancer, Patrick Micke